Century Capital Management LLC cut its stake in bluebird bio, Inc. (NASDAQ:BLUE) by 7.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 20,643 shares of the company’s stock after selling 1,693 shares during the period. Century Capital Management LLC owned approximately 0.06% of bluebird bio worth $1,274,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also recently modified their holdings of BLUE. Capital Fund Management S.A. increased its position in shares of bluebird bio by 1,233.8% in the second quarter. Capital Fund Management S.A. now owns 6,803 shares of the company’s stock valued at $295,000 after buying an additional 7,403 shares in the last quarter. CAM Group Holding A S increased its position in shares of bluebird bio by 28.0% in the second quarter. CAM Group Holding A S now owns 6,400 shares of the company’s stock valued at $277,000 after buying an additional 1,400 shares in the last quarter. Emerald Acquisition Ltd. purchased a new position in shares of bluebird bio during the second quarter valued at $255,000. JPMorgan Chase & Co. increased its position in shares of bluebird bio by 43.0% in the second quarter. JPMorgan Chase & Co. now owns 85,235 shares of the company’s stock valued at $3,690,000 after buying an additional 25,612 shares in the last quarter. Finally, Teacher Retirement System of Texas increased its position in shares of bluebird bio by 25.3% in the second quarter. Teacher Retirement System of Texas now owns 5,114 shares of the company’s stock valued at $221,000 after buying an additional 1,034 shares in the last quarter.
Shares of bluebird bio, Inc. (NASDAQ:BLUE) opened at 75.70 on Friday. The company has a 50-day moving average of $68.84 and a 200-day moving average of $62.14. The stock’s market capitalization is $2.82 billion. bluebird bio, Inc. has a 52-week low of $35.37 and a 52-week high of $79.70.
ILLEGAL ACTIVITY WARNING: This piece was first reported by sleekmoney and is the property of of sleekmoney. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at http://sleekmoney.com/bluebird-bio-inc-blue-stake-cut-by-century-capital-management-llc/1656692.html.
Several research analysts have commented on BLUE shares. BTIG Research reissued a “buy” rating and set a $83.00 price objective (up previously from $72.00) on shares of bluebird bio in a report on Saturday, October 15th. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and set a $135.00 price objective on shares of bluebird bio in a report on Saturday, October 15th. Jefferies Group LLC set a $80.00 price objective on shares of bluebird bio and gave the company a “buy” rating in a report on Saturday, October 15th. Cowen and Company reissued an “outperform” rating on shares of bluebird bio in a report on Monday, October 17th. Finally, Zacks Investment Research raised shares of bluebird bio from a “sell” rating to a “hold” rating in a report on Tuesday, October 18th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twelve have assigned a buy rating to the company. bluebird bio has an average rating of “Buy” and an average price target of $84.36.
In other bluebird bio news, Director Daniel Lynch sold 1,000 shares of bluebird bio stock in a transaction that occurred on Friday, January 27th. The stock was sold at an average price of $70.09, for a total transaction of $70,090.00. Following the sale, the director now directly owns 2,400 shares of the company’s stock, valued at approximately $168,216. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director James Mandell sold 8,000 shares of bluebird bio stock in a transaction that occurred on Tuesday, January 31st. The shares were sold at an average price of $75.04, for a total value of $600,320.00. Following the sale, the director now directly owns 9,000 shares in the company, valued at $675,360. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 15,549 shares of company stock worth $1,121,368. Insiders own 3.50% of the company’s stock.
bluebird bio Company Profile
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio, Inc. (NASDAQ:BLUE).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/bluebird-bio-inc-blue-stake-cut-by-century-capital-management-llc/1656692.html
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.